住院恶性肿瘤患者Khorana评分分布调查及模型改良

doi:10.3760/cma.j.issn.1007-1245.2024.12.012

摘要/Abstract

摘要：

目的　调查住院恶性肿瘤患者Khorana评分分布，分析住院恶性肿瘤患者发生静脉血栓栓塞（venous thromboembolism，VTE）的危险因素，探讨改良Khorana评分模型预测住院恶性肿瘤患者VTE风险的价值。方法　回顾性分析2019年11月至2022年10月潍坊市人民医院收治的389例恶性肿瘤患者的临床资料，其中男性233例、女性156例，年龄（57.95±11.71）岁。采用Khorana评分进行VTE风险评估，统计患者VTE发生情况。采用独立样本t检验、χ²检验、logistic回归分析、受试者操作特征曲线（receiver operating characteristic curve，ROC）进行分析。结果　389例恶性肿瘤患者中19例发生VTE，发生率为4.88%。Khorana评分0、1、2、≥3分患者占比分别为36.25%（141/389）、37.79%（147/389）、19.54%（76/389）、6.43%（25/389），对应VTE发生率为2.84%（4/141）、4.08%（6/147）、7.89%（6/76）、12.00%（3/25），Khorana评分越高VTE发生率也更高，但差异无统计学意义（χ²=4.936，P=0.177）。有、无饮酒史患者Khorana评分≤2分的占比分别为95.16%（118/124）、92.83%（246/265）（P<0.05）。冠心病、高危VTE癌种及高D-二聚体为住院恶性肿瘤患者发生VTE的危险因素（OR=3.844、2.010、1.102，均P<0.05），其中冠心病为独立危险因素（校正OR=4.048，P=0.023）。改良Khorana评分对住院恶性肿瘤患者VTE发生风险的预测灵敏度、特异度和约登指数分别为68.421%、68.378%和0.368（P<0.01），其曲线下面积（0.684）较Khorana评分（0.549）增加了0.135，预测价值更高（Z=2.251，P=0.018）。结论　住院恶性肿瘤患者Khorana评分越高，VTE发生率越高，但Khorana评分预测价值不高，冠心病是住院恶性肿瘤患者发生VTE的独立危险因素，结合D-二聚体的改良Khorana评分对住院恶性肿瘤患者VTE发生风险的预测价值高于Khorana评分。

关键词:

恶性肿瘤, Khorana评分, 静脉血栓栓塞, D-二聚体

Abstract:

Objective　To investigate the distribution of Khorana score and risk factors of venous thromboembolism (VTE) in hospitalized patients with malignant tumors, and to explore the value of modified Khorana score model in predicting the risk of VTE in hospitalized patients with malignant tumors. Methods　The clinical data of 389 hospitalized patients with malignant tumors admitted to Weifang People's Hospital from November 2019 to October 2022 were retrospectively analyzed, including 233 males and 156 females, aged (57.95±11.71) years. The Khorana score was used to assess the risk of VTE, and the incidence of VTE was calculated. Independent sample t test, χ² test, logistic regression analysis, and receiver operating characteristic curve (ROC) were used for analysis. Results　Among the 389 patients, 19 occurred VTE, with an overall incidence of 4.88%. The proportions of the patients with Khorana score of 0, 1, 2, and ≥3 points were 36.25% (141/389), 37.79% (147/389), 19.54% (76/389), and 6.43% (25/389), respectively. The corresponding incidences of VTE were 2.84% (4/141), 4.08% (6/147), 7.89% (6/76), and 12.00% (3/25). The higher the Khorana score was, the higher the incidence of VTE was, but the difference was not statistically significant (χ²=4.936, P=0.177). The rates of Khorana score ≤2 points in the patients with or without drinking history were 95.16% (118/124) and 92.83% (246/265) (P<0.05). Coronary heart disease, high-risk VTE cancer, and high D-dimer were the risk factors for VTE in hospitalized patients with malignant tumors (OR=3.844, 2.010, and 1.102, all P<0.05), among which coronary heart disease was an independent risk factor (OR=4.048, P=0.023). The sensitivity, specificity, and Youden index of modified Khorana score for predicting the risk of VTE in hospitalized patients with malignant tumors were 68.421%, 68.378%, and 0.368 (P<0.01), respectively, and the area under the curve (AUC) was increased by 0.135 compared with the original score, with higher predicted value (Z=2.251, P=0.018). Conclusions　The higher the Khorana score, the higher the incidence of VTE, but its predictive value is not high. Coronary heart disease is an independent risk factor for VTE in hospitalized patients with malignant tumors. Modified Khorana score combined with D-dimer has a higher predictive value for the risk of VTE in in hospitalized patients with malignant tumors than the original score.

Key words:

Malignant tumors, Khorana score, Venous thromboembolism, D-dimer

高珂琴秦晓春刘朋川.

住院恶性肿瘤患者Khorana评分分布调查及模型改良 [J]. 国际医药卫生导报, 2024, 30(12): 1993-1998.

Gao Keqin, Qin Xiaochun, Liu Pengchuan.

Distribution and modification of Khorana score in hospitalized patients with malignant tumors [J]. International Medicine and Health Guidance News, 2024, 30(12): 1993-1998.

参考文献

[1] Min L, Bao H, Bu F, et al. Machine-learning-assisted procoagulant extracellular vesicle barcode assay toward high-performance evaluation of thrombosis-induced death risk in cancer patients[J]. ACS Nano, 2023, 17(20):19914-19924. DOI: 10.1021/acsnano.3c04615.
[2] 中国临床肿瘤学会肿瘤与血栓专家委员会. 肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J]. 中国肿瘤临床,2019,46(13):653-660. DOI:10.3969/j.issn.1000-8179. 2019.13.765.
[3] Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis[J]. Blood, 2008, 111(10):4902-4907. DOI: 10.1182/blood-2007-10- 116327.
[4] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)肿瘤患者静脉血栓防治指南-2020[M]. 北京:人民卫生出版社,2020.
[5] Qin Y, Liang X, Wu H, et al. Development and validation of a modified khorana score for predicting venous thromboembolism in newly diagnosed stage IV lung cancer[J]. Angiology, 2023, 4:33197231213197. DOI: 10.1177/00033197231213197.
[6] Qin L, Liang Z, Xie J, et al. Estimating venous thromboembolism risk in metastatic colorectal cancer inpatients: validation of existing risk scores and development of new risk scores[J]. Clin Appl Thromb Hemost, 2023, 29:10760296231196859. DOI: 10.1177/10760296231196859.
[7] 黄菊,邵群. 肿瘤相关静脉血栓栓塞症的预防与治疗进展[J]. 中华医学杂志,2024,104(2):152-157. DOI:10.3760/cma.j.cn112137-20230920-00507.
[8] Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer[J]. Blood Adv, 2021, 5(4):927-974. DOI: 10.1182/bloodadvances.2020003442.
[9] Rubio-Jurado B, Balderas-Peña LM, García-Luna EE, et al. Obesity, thrombotic risk, and inflammation in cancer[J]. Adv Clin Chem, 2018, 85:71-89. DOI: 10.1016/bs.acc.2018.02.006.
[10] Xu J, Wang G, Chen X, et al. Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study[J]. Thromb J, 2023, 21(1):15. DOI: 10.1186/s12959-023-00456-9.
[11] Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity[J]. J Thromb Haemost, 2023, 21(6):1397-1408. DOI: 10.1016/j.jtha.2023.02.029.
[12] 宋丹. ≥60岁住院PICC置管患者深静脉血栓危险因素分析[J]. 国际医药卫生导报,2022,28(4):552-555. DOI:10.3760/cma.j.issn.1007-1245.2022.04.027.
[13] Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer[J]. N Engl J Med, 2019, 380(8):711-719. DOI: 10.1056/NEJMoa1814468.
[14] 张甲燚,陈玲,周宏,等. 肺肿瘤性血栓性微血管病的早期识别与处理[J]. 国际呼吸杂志,2023,43(7):745-751. DOI:10.3760/cma.j.cn131368-20230425-00268.
[15] Verheugt FWA, Fox KAA, Virdone S, et al. Outcomes of oral anticoagulation in atrial fibrillation patients with or without comorbid vascular disease: insights from the GARFIELD-AF registry[J]. Am J Med, 2023, 136(12):1187-1195.e15. DOI: 10.1016/j.amjmed.2023.08.019.
[16] Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study[J]. Oncologist, 2017, 22(10):1222-1231. DOI: 10.1634/theoncologist.2016-0414.
[17] Mulder FI, Candeloro M, Kamphuisen PW, et al. The khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis[J]. Haematologica, 2019, 104(6):1277-1287. DOI: 10.3324/haematol.2018.209114.
[18] Zhang X, Chen X, Yang J, et al. Meta-analysis of alcohol consumption and venous thromboembolism[J]. J Public Health (Oxf), 2022, 44(3):477-498. DOI: 10.1093/pubmed/fdab045.
[19] Chen M, Ji M, Chen T, et al. Alcohol consumption and risk for venous thromboembolism: a meta-analysis of prospective studies[J]. Front Nutr, 2020,7:32. DOI: 10.3389/fnut.2020.00032.
[20] Johansson M, Johansson L, Wennberg M, et al. Alcohol consumption and risk of first-time venous thromboembolism in men and women[J]. Thromb Haemost, 2019,119(6):962-970. DOI: 10.1055/s-0039-1681100.
[21] Maia R, Neves I, Morais A,et al. Venous and lung thromboembolism in the context of lung cancer: clinical manifestations, risk factors and prognosis[J]. Acta Med Port, 2019, 32(10):647-653. DOI: 10.20344/amp.10260.
[22] 姚宇婷. 恶性肿瘤合并静脉血栓栓塞症临床特征及风险预测模型的评估[D]. 蚌埠: 蚌埠医学院,2022.DOI:10.26925/d.cnki.gbbyc.2021.000047.
[23] Lyman GH, Culakova E, Poniewierski MS, et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer[J]. Thromb Res, 2018, 164 Suppl 1:S112-S118. DOI: 10.1016/j.thromres.2018.01.028.
[24] Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models[J]. Cancers (Basel), 2019, 11(1):95. DOI: 10.3390/cancers11010095.
[25] Hiraide M, Shiga T, Minowa Y, et al. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients[J]. J Cardiol, 2020, 75(1):110-114. DOI: 10.1016/j.jjcc.2019.06.013.
[26] Reitter EM, Kaider A, Ay C, et al. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment[J]. J Thromb Haemost, 2016, 14(2):294-305. DOI: 10.1111/jth.13218.
[27] 王菲,王云飞,张志宇,等. 血清D-二聚体及肿瘤标志物水平预测老年Ⅲ~Ⅳ期肺腺癌患者合并静脉血栓栓塞的价值[J]. 中国实用医刊,2023,50(18):20-24. DOI:10.3760/cma.j.cn115689-20230606-02339.
[28] Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients[J]. Blood, 2010, 116(24):5377-5382. DOI: 10.1182/blood-2010-02- 270116.
[29] Niimi K, Nishida K, Lee C, et al. Optimal D-dimer cutoff values for diagnosing deep vein thrombosis in patients with comorbid malignancies[J]. Ann Vasc Surg, 2024, 98:293-300. DOI: 10.1016/j.avsg.2023.06.033.
[30] Li S, Gao P, Qiu J, et al. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer[J]. J Thromb Thrombolysis, 2021, 52(3):898-903. DOI: 10.1007/s11239-021-02396-5.
[31] 陈丽霞,李博,韩永清. 凝血指标D-Dimer联合Khorana评分模型预测肿瘤患者化疗后静脉血栓风险的价值[J]. 现代肿瘤医学,2023,31(9):1712-1715. DOI:10.3969/j.issn.1672- 4992.2023.09.024.